Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleCardiovascular

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION

Frederic Trensz, Celine Bortolamiol, Markus Kramberg, Daniel Wanner, Hakim Hadana, Markus Rey, Daniel S Strasser, Stephane Delahaye, Patrick Hess, Enrico Vezzali, Ulrich Mentzel, Joel Menard, Martine Clozel and Marc Iglarz
Journal of Pharmacology and Experimental Therapeutics January 8, 2019, jpet.118.253864; DOI: https://doi.org/10.1124/jpet.118.253864
Frederic Trensz
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Celine Bortolamiol
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Kramberg
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Wanner
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hakim Hadana
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Markus Rey
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel S Strasser
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephane Delahaye
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hess
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Enrico Vezzali
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ulrich Mentzel
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Menard
2 Centre de Recherche des Cordeliers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martine Clozel
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Iglarz
1 Idorsia Pharmaceuticals Ltd.;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF
Loading

Abstract

The endothelin (ET) system has emerged as a novel target for hypertension treatment where a medical need persists despite availability of several pharmacological classes, including renin angiotensin system (RAS) blockers. ET receptor antagonism has demonstrated efficacy in preclinical models of hypertension, especially in low-renin conditions, and in hypertensive patients. We investigated the pharmacology of aprocitentan (ACT-132577), a potent dual ETA/ETB receptor antagonist, on blood pressure (BP) in two models of experimental hypertension: DOCA-Salt rats (low-renin model) and spontaneously hypertensive rats (SHR, normal renin model). We also compared the effect of its combination with RAS blockers (valsartan and enalapril) with that of the combination of the mineraloreceptor antagonist spironolactone with the same RAS blockers on BP and renal function in hypertensive rats. Aprocitentan was more potent and efficacious in lowering BP in conscious DOCA-salt rats than in SHR. In DOCA-salt rats, single oral doses of aprocitentan induced a dose-dependent and long-lasting BP decrease and 4-week administration of aprocitentan dose-dependently decreased BP (statistically significant) and renal vascular resistance and reduced left ventricle hypertrophy (non-significant). Aprocitentan was synergistic with valsartan and enalapril in decreasing BP in DOCA-salt rats and SHR while spironolactone demonstrated additive effects with these RAS blockers. In hypertensive rats under sodium restriction and enalapril, addition of aprocitentan further decreased BP without causing renal impairment, in contrast to spironolactone. In conclusion, ETA/ETB receptor antagonism represents a promising therapeutic approach in hypertension especially with low-renin characteristics and could be used in combination with RAS blockers, without increasing the risk of renal impairment.

  • aldosterone
  • blood pressure
  • drug discovery
  • endothelin receptors
  • hypertension
  • renin-angiotensin system (RAS)
  • The American Society for Pharmacology and Experimental Therapeutics
Next
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 376 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 376, Issue 3
1 Mar 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleCardiovascular

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION

Frederic Trensz, Celine Bortolamiol, Markus Kramberg, Daniel Wanner, Hakim Hadana, Markus Rey, Daniel S Strasser, Stephane Delahaye, Patrick Hess, Enrico Vezzali, Ulrich Mentzel, Joel Menard, Martine Clozel and Marc Iglarz
Journal of Pharmacology and Experimental Therapeutics January 8, 2019, jpet.118.253864; DOI: https://doi.org/10.1124/jpet.118.253864

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleCardiovascular

PHARMACOLOGICAL CHARACTERIZATION OF APROCITENTAN, A DUAL ENDOTHELIN RECEPTOR ANTAGONIST, ALONE AND IN COMBINATION WITH BLOCKERS OF THE RENIN ANGIOTENSIN SYSTEM, IN TWO MODELS OF EXPERIMENTAL HYPERTENSION

Frederic Trensz, Celine Bortolamiol, Markus Kramberg, Daniel Wanner, Hakim Hadana, Markus Rey, Daniel S Strasser, Stephane Delahaye, Patrick Hess, Enrico Vezzali, Ulrich Mentzel, Joel Menard, Martine Clozel and Marc Iglarz
Journal of Pharmacology and Experimental Therapeutics January 8, 2019, jpet.118.253864; DOI: https://doi.org/10.1124/jpet.118.253864
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF + SI
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Improved Assessment of Cardiovascular Safety Data
  • β3-Agonist Improves Myocardial Stiffness
  • A Novel Inhibitor of Myocardial mPTP
Show more Cardiovascular

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics